Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-vascular endothelial growth factor antibody and fusion protein with hepcidin

A technology of endothelial growth factor and fusion protein, which is applied in the field of single-chain antibody and fusion protein with hepcidin, can solve the problems that it is difficult to guarantee the synergistic effect and the anti-tumor effect is difficult to achieve a satisfactory effect, and achieve enhanced anti-tumor effect, broaden anti-tumor methods, and reduce production costs

Active Publication Date: 2018-01-05
北京格根生物科技有限公司
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although bispecific antibodies have good tumor recognition ability, they often need to use other regulatory proteins or cells to promote the body to produce anti-tumor effects. Therefore, it is difficult to ensure efficient synergistic effects, and its anti-tumor effects are still difficult to achieve. Effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-vascular endothelial growth factor antibody and fusion protein with hepcidin
  • Anti-vascular endothelial growth factor antibody and fusion protein with hepcidin
  • Anti-vascular endothelial growth factor antibody and fusion protein with hepcidin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Preparation of anti-VEGF bispecific antibody

[0033] 1.1 Establishment of high-capacity natural antibody library.

[0034] Separation of human peripheral blood mononuclear lymphocytes: 100 healthy adults were randomly selected, and 10ml of peripheral blood was extracted from each person. Dilute 1:1 with RPMI-1640 culture medium containing 10% heparin, add to the centrifuge tube containing lymphocyte separation medium (the volume ratio of diluted venous blood to lymphocyte separation medium is 2:1), 2,000×g, Centrifuge for 17 minutes. Aspirate the milky white mononuclear cell layer at the interface of the lymphocyte separation solution, and wash twice with PBS buffer.

[0035] 1.2 Extraction of total cellular RNA

[0036] Press every 5×10 6 The ratio of cells / ml was added to Trizol reagent, and the cells were lysed by pipetting. Incubate at room temperature for 5 minutes, transfer to a DEPC-treated EP tube, add 1 / 5 volume of chloroform, shake vigorously f...

Embodiment 2

[0077] Example 2. Construction of fusion protein

[0078] Hepcidin DNA and selected linker DNA were biosynthesized and linked to VEGF ScFv DNA using PCR technology.

[0079] PCR reaction reaction system:

[0080]

[0081] Add deionized water to a final volume of 50 μl.

[0082] PCR parameters: After denaturation at 94°C for 3 minutes, PCR was performed at 94°C for 30 seconds; at 61°C for 30 seconds; at 72°C for 1 minute, for a total of 30 cycles, and finally at 72°C for 10 minutes. After the reaction, 5 μl of the reaction product was taken for 1% agarose gel electrophoresis analysis.

[0083] Ligation reaction reaction system:

[0084]

[0085] After the above reactants were well mixed and centrifuged to sink to the bottom of the tube, they were connected overnight at 4°C.

[0086] Transformation of the recombinant plasmid (the steps are the same as before).

[0087] Sequence analysis of DNA fragments of positive clones.

[0088] For the positive clones identified by...

Embodiment 3

[0103] Example 3. The inhibitory effect of fusion protein on the growth of different breast cancer cells

[0104] Use Transwell small chamber (type 3428, pore size 8um, US Corning-Costar Company) to measure cell invasion in vitro (perform according to the operating instructions)

[0105] Preparation of conditioned medium (as a chemokine): mouse fibroblast cell line NIH3T3, cultured with RPMI-1640 medium containing 10% calf serum at 37°C and 5% CO2, and changed to serum-free when the growth was good After culturing the culture solution for 24 hours, the supernatant was collected, sterilized by filtration, and frozen for future use.

[0106] 200ul / well of extracellular matrix was coated on the bottom of the Transwell chamber, and polymerized in a 37°C incubator for 1 hour.

[0107] Add 1 ml of high-sugar DMEM medium containing 0.1% BSA to the 6-well plate and hydrate the basement membrane at 37°C for 30 minutes.

[0108] Aspirate the culture medium, add 2.5ml of conditioned me...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-vascular endothelial growth factor single-chain antibody and protein thereof fused with hepcidin protein. The single-chain antibody has a highly specific antigen recognition capability. The fusion protein not only has a specific recognition function of an antibody, but also has an excellent anti-tumor effect; the fusion protein has obvious growth inhibition effectsto all three different types of lung cancer cell lines; in animal experiments, lung tumor tissues of mice are significantly reduced compared with those of a control group, moreover the antibody fusionprotein is small in molecular weight, expression in a prokaryotic cell expression system is realized, and the production cost of antibody drugs is greatly reduced.

Description

technical field [0001] The invention discloses a single-chain antibody and a fusion protein with hepcidin, belonging to the fields of immunology and molecular biology. Background technique [0002] Tumor is the biggest disease that threatens human survival. The World Health Organization research shows that in 2012, the number of cancer patients in China was 3.065 million, accounting for about one-fifth of the global incidence; the number of cancer deaths was 2.205 million, accounting for about one-quarter of the global cancer deaths. The formation and development of tumors have a very complex regulatory mechanism, and many biological effector molecules are involved in it. Clarifying the mechanism of action of these biological effector molecules is of great significance for the prevention and treatment of tumor diseases. It has been found in the prior art that both vascular endothelial growth factor (Vascular Endothelial Growth Factor, VEGF) and hepcidin are involved in the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/22C07K19/00A61K38/17A61K39/395A61P35/00
Inventor 满来谢珞琨李峥
Owner 北京格根生物科技有限公司